PT-141 (Bremelanotide)
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist developed from the α-MSH analog Melanotan II and studied as a ligand of MC3R and MC4R in sexual-function models; the research catalog lists it at https://onesourcepeptides.com/product/pt-141.
PT-141 entered the literature as a central melanocortin probe. Molinoff et al., Annals of the New York Academy of Sciences, 2003 (PMID 12851303) describe it as a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone that acts as an agonist at melanocortin receptors, with early work focused on MC3R and MC4R pathways that link the peptide to arousal physiology in preclinical and early clinical models rather than to peripheral vascular mechanisms alone.
Pharmacodynamic work followed quickly. Rosen et al., International Journal of Impotence Research, 2004 (PMID 14999221) evaluated subcutaneous PT-141 for safety, pharmacokinetics and pharmacodynamic effects in healthy men and in men with an inadequate response to sildenafil, reporting receptor-consistent erectile responses and a tolerability profile that supported further study of the melanocortin route. A complementary early trial by Diamond et al., Journal of Sexual Medicine, 2006 (PMID 16839319) tested a single intranasal dose in premenopausal women with sexual arousal disorder and reported higher rates of moderate or high desire versus placebo within 24 hours.
Later phase 3 programs put the ligand through larger controlled trials. Kingsberg et al., Obstetrics & Gynecology, 2019 (PMID 31599840) report the two identical RECONNECT randomized trials (NCT02333071, NCT02338960), in which subcutaneous bremelanotide produced statistically significant gains on desire and distress endpoints versus placebo. Related notes cover VIP and Kisspeptin-10, and lot identity belongs on the certificate of analysis for the vial in hand (see Are research peptides third-party tested?). PT-141 on the catalog is laboratory research supply only. This note summarizes published melanocortin-receptor research and is not dosing, reconstitution, or human-use guidance.